Company Watch

Dr Reddy's launched 'Atocor-R'

Our News Bureau - Mumbai

Dr Reddy's Laboratories has launched Atocor-R (atorvastatin + ramipril) in India. It is the first such combination to be approved by DCGI and has completed a multicentre clinical trial data on Indian patients. It is a one of its kind combination that has two blockbuster molecules, atorvastatin and ramipril combined together for the first time as a fixed dose combination. Atocor-R is used in the treatment of patients with both essential hypertension and hypercholesterolemia. It is available in two fixed dose combinations of Atocor-R 2.5 (atorvastatin 10mg + ramipril 2.5 mg ) and Atocor-R 5 (atorvastatin 10mg + ramipril 5 mg) and comes in packs of 10.

Atorvastatin is a world largest cholesterol lowering drug and ramipril is a proven cardioprotective agent and these two drugs have a combined domestic market of around Rs 450 crore per annum. The atorvastatin market is currently valued at Rs 300 crore and is growing at over 34 per cent annually. The ramipril market is about Rs 145 crore, growing at over 15 percent annually, the company informed.